清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial

医学 替卡格雷 阿司匹林 冲程(发动机) 内科学 心肌梗塞 心脏病学 随机对照试验 临床终点 子群分析 氯吡格雷 置信区间 机械工程 工程类
作者
Pierre Amarenco,Gregory W. Albers,Hans Denison,J. Donald Easton,Scott R. Evans,Peter Held,Michael D. Hill,Jenny Jonasson,Scott E. Kasner,Per Ladenvall,Kazuo Minematsu,Carlos A. Molina,Yongjun Wang,K. H. Yau Wong,S. Claiborne Johnston
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (4): 301-310 被引量:155
标识
DOI:10.1016/s1474-4422(17)30038-8
摘要

Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin. Our aim was to test for a treatment-by-ipsilateral atherosclerotic stenosis interaction in a subgroup analysis of patients in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial.SOCRATES was a randomised, double-blind, controlled trial of ticagrelor versus aspirin in patients aged 40 years or older with a non-cardioembolic, non-severe acute ischaemic stroke, or high-risk transient ischaemic attack from 674 hospitals in 33 countries. We randomly allocated patients (1:1) to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-90, given orally) or aspirin (300 mg on day 1 followed by 100 mg daily for days 2-90, given orally) within 24 h of symptom onset. Investigators classified all patients into atherosclerotic and non-atherosclerotic groups for the prespecified, exploratory analysis reported in this study. The primary endpoint was the time to occurrence of stroke, myocardial infarction, or death within 90 days. Efficacy analysis was by intention to treat. The SOCRATES trial is registered with ClinicalTrials.gov, number NCT01994720.Between Jan 7, 2014, and Oct 29, 2015, we randomly allocated 13 199 patients (6589 [50%] to ticagrelor and 6610 [50%] to aspirin). Potentially symptomatic ipsilateral atherosclerotic stenosis was reported in 3081 (23%) of 13 199 patients. We found a treatment-by-atherosclerotic stenosis interaction (p=0·017). 103 (6·7%) of 1542 patients with ipsilateral stenosis in the ticagrelor group and 147 (9·6%) of 1539 patients with ipsilateral stenosis in the aspirin group had an occurrence of stroke, myocardial infarction, or death within 90 days (hazard ratio 0·68 [95% CI 0·53-0·88]; p=0·003). In 10 118 patients with no ipsilateral stenosis, 339 (6·7%) of 5047 patients in the ticagrelor group had an occurrence of stroke, myocardial infarction, or death within 90 days compared with 350 (6·9%) of 5071 in the aspirin group (0·97 [0·84-1·13]; p=0·72). There were no significant differences in the proportion of life-threatening bleeding or major or minor bleeding events in patients with ipsilateral stenosis in the ticagrelor group compared with the aspirin group.In this prespecified exploratory analysis, ticagrelor was superior to aspirin at preventing stroke, myocardial infarction, or death at 90 days in patients with acute ischaemic stroke or transient ischaemic attack when associated with ipsilateral atherosclerotic stenosis. An understanding of stroke mechanisms and causes is important to deliver safe and efficacious treatments for early stroke prevention.AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可爱的函函的应助被小文同学采纳,获得10
3秒前
平静完成签到 ,获得积分10
10秒前
Nefelibata完成签到 ,获得积分10
12秒前
吴日官完成签到,获得积分10
28秒前
笨笨完成签到 ,获得积分10
31秒前
Magic完成签到 ,获得积分10
33秒前
yinyin完成签到 ,获得积分10
34秒前
jiayouliyi完成签到 ,获得积分10
45秒前
许安完成签到 ,获得积分10
52秒前
小狮子完成签到 ,获得积分10
1分钟前
mickaqi完成签到 ,获得积分10
1分钟前
369ninja的应助被远远采纳,获得10
1分钟前
饼饼完成签到,获得积分20
1分钟前
wanghao完成签到 ,获得积分10
1分钟前
左丘映易完成签到,获得积分0
1分钟前
活泼的小七完成签到,获得积分10
1分钟前
饼饼发布了新的文献求助30
1分钟前
回首不再是少年完成签到,获得积分0
1分钟前
流云若雨初时模样完成签到 ,获得积分10
1分钟前
追梦完成签到,获得积分10
1分钟前
震动的念波完成签到 ,获得积分10
2分钟前
Vintoe完成签到 ,获得积分10
2分钟前
如泣草芥完成签到,获得积分10
2分钟前
如我所愿完成签到 ,获得积分10
2分钟前
xiaofeixia完成签到 ,获得积分10
2分钟前
kidpan完成签到,获得积分20
2分钟前
Dino完成签到 ,获得积分10
2分钟前
马说完成签到 ,获得积分10
2分钟前
agathahqs的应助被正常糖采纳,获得20
2分钟前
在水一方的应助被听话的尔竹采纳,获得10
2分钟前
樊新竹完成签到,获得积分10
2分钟前
Maestro_S的应助被科研通管家采纳,获得10
2分钟前
李爱国的应助被科研通管家采纳,获得10
2分钟前
r41r32完成签到 ,获得积分10
3分钟前
大雪完成签到 ,获得积分10
3分钟前
阿努比斯完成签到 ,获得积分10
3分钟前
gd完成签到 ,获得积分10
3分钟前
ni完成签到 ,获得积分10
3分钟前
希望天下0贩的0的应助被阿亮采纳,获得10
3分钟前
岳晓燕完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195281
求助须知:如何正确求助?哪些是违规求助? 9580992
关于积分的说明 21873180
捐赠科研通 7795382
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561346
邀请新用户注册赠送积分活动 2484713